



**U. S. Department of Justice**  
**Drug Enforcement Administration**

8701 Morrissette Drive  
Springfield, VA 22152

---

*www.dea.gov*

**JAN 17 2020**

Delaram J. Taghipour, M.D.  
Michael A. Carome, M.D.  
Sidney M. Wolfe, M.D.  
Public Citizen  
1600 20th Street, NW  
Washington, D.C. 20009

Drs. Taghipour, Carome and Wolfe:

This is in response to your November 6, 2019, letter petitioning the Drug Enforcement Administration (DEA) to initiate proceedings for the rescheduling of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, its optical and geometric isomers, and salts of these isomers (including tramadol) from schedule IV to schedule II of the Controlled Substances Act. The petition substantially complies procedurally with the requirements of 21 CFR § 1308.43 (b) and the DEA is therefore accepting the petition for filing.

If you should have further questions relating to your petition, please feel free to contact Terrence Boos, Ph.D., Section Chief, Drug and Chemical Evaluation Section, at (571) 362-3249.

Sincerely,

A handwritten signature in black ink, appearing to read "Brian Besser".

Brian Besser  
Deputy Assistant Administrator  
Diversion Control Division